TIDMACPH 
 

Acacia Pharma Group plc: Results of Annual General Meeting

Cambridge, UK and Indianapolis, US -- 29 June 2021: Acacia Pharma Group plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH) announces that all resolutions as set out in the Notice of Annual General Meeting dated 25 May 2021 were duly passed by the required majority at the Annual General Meeting ("AGM") held yesterday.

The results of the votes on the resolutions are shown in the table below and will be posted on the Company's website at www.acaciapharma.com in the Investors/Shareholder Meetings section.

 
                                                                    Votes                Votes        Votes 
  Resolution                               Votes for       %        against     %        total       withheld 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To receive the consolidated 
   financial statements 
   and the reports of the 
   Directors and the auditor 
   for the year ended 31 
   December 2020                           51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To approve the Directors' 
   Remuneration Policy                     51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To approve the Directors' 
   Remuneration Report                     51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To re-elect Scott Byrd 
   as a Director of the 
   Company                                 51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To re-elect Michael 
   Bolinder as a Director 
   of the Company                          51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To re-elect Edward Borkowski 
   as a Director of the 
   Company                                 51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To re-elect John Brown 
   as a Director of the 
   Company                                 51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To elect Alessandro 
   Della Chá who was 
   appointed as a Director 
   of the Company since 
   the last Annual General 
   Meeting, as a Director 
   of the Company                          51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To re-appoint PricewaterhouseCoopers 
   LLP as auditor of the 
   Company                                 51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To authorise the Directors 
   of the Company to agree 
   the remuneration of 
   the Company's auditor                   51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  Allotment of Shares                      51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To disapply pre-emption 
   rights                                  51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
  To resolve to amend 
   the Articles of Association             51,451,342    100.00           0    0.00    51,451,342           0 
---------------------------------------  ------------  --------  ----------  ------  ------------  ---------- 
 

As at the close of business on 24 June 2021 (being the time at which shareholders who wanted to attend and vote at the meeting were required to have their details entered in the register of members) there were 99,713,951 shares of 2p each in issue.

Contacts

 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   MEDiSTRAVA Consulting 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@medistrava.com 
US Investors                        Media in Belgium and the Netherlands 
 LifeSci Advisors                    Chris Van Raemdonck 
 Irina Koffler                       +32 499 58 55 31 
 +1 917-734-7387                     chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
 

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

Acacia Pharma Group plc

The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom

Company number 9759376

www.acaciapharma.com

 
 

(END) Dow Jones Newswires

June 29, 2021 01:00 ET (05:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Acacia Pharma Charts.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Acacia Pharma Charts.